AbstractMost HIV-1 vaccines elicit neutralizing antibodies that are active against highly sensitive (tier-1) viruses or rare cases of vaccine-matched neutralization-resistant (tier-2) viruses, but no vaccine has induced antibodies that can broadly neutralize heterologous tier-2 viruses. In this study, we isolated antibodies from an HIV-1-infected individual that targeted the gp41 membrane-proximal external region (MPER) that may have selected single-residue changes in viral variants in the MPER that resulted in neutralization sensitivity to antibodies targeting distal epitopes on the HIV-1 Env. Similarly, a single change in the MPER in a second virus from another infected-individual also conferred enhanced neutralization sensitivity. These ...
<div><p>A comprehensive understanding of the regions on HIV-1 envelope trimers targeted by broadly n...
Human Immunodeficiency Virus (HIV-1) is an epidemic that affects over 34 million people worldwide. A...
The broadly neutralizing human monoclonal antibodies (MAbs) 2F5 and 4E10, both targeting the highly ...
Most HIV-1 vaccines elicit neutralizing antibodies that are active against highly sensitive (tier-1)...
<div><p>Human antibody 10E8 targets the conserved membrane proximal external region (MPER) of envelo...
International audienceHIV-1 vaccine research has obtained an enormous boost since the discovery of m...
Potent and broadly neutralizing antibodies (bnAbs) are the hallmark of HIV-1 protection by vaccinati...
AbstractThe detailed interactions between antibodies and the HIV-1 envelope protein that lead to neu...
HIV-1 affects over 34 million people worldwide. Although there is no vaccine, some patients develop ...
Although human immunodeficiency type 1 (HIV-1) infection induces strong antibody responses to the vi...
Broadly neutralizing antibodies are not commonly produced in HIV-1 infected individuals nor by exper...
International audiencePotent and broadly neutralizing antibodies (bnAbs) are the hallmark of HIV-1 p...
Broadly neutralizing antibodies are not commonly produced in HIV-1 infected individuals nor by exper...
Although human immunodeficiency type 1 (HIV-1) infection induces strong antibody responses to the vi...
The generation of broadly neutralizing antibodies is a priority in the design of vaccines against HI...
<div><p>A comprehensive understanding of the regions on HIV-1 envelope trimers targeted by broadly n...
Human Immunodeficiency Virus (HIV-1) is an epidemic that affects over 34 million people worldwide. A...
The broadly neutralizing human monoclonal antibodies (MAbs) 2F5 and 4E10, both targeting the highly ...
Most HIV-1 vaccines elicit neutralizing antibodies that are active against highly sensitive (tier-1)...
<div><p>Human antibody 10E8 targets the conserved membrane proximal external region (MPER) of envelo...
International audienceHIV-1 vaccine research has obtained an enormous boost since the discovery of m...
Potent and broadly neutralizing antibodies (bnAbs) are the hallmark of HIV-1 protection by vaccinati...
AbstractThe detailed interactions between antibodies and the HIV-1 envelope protein that lead to neu...
HIV-1 affects over 34 million people worldwide. Although there is no vaccine, some patients develop ...
Although human immunodeficiency type 1 (HIV-1) infection induces strong antibody responses to the vi...
Broadly neutralizing antibodies are not commonly produced in HIV-1 infected individuals nor by exper...
International audiencePotent and broadly neutralizing antibodies (bnAbs) are the hallmark of HIV-1 p...
Broadly neutralizing antibodies are not commonly produced in HIV-1 infected individuals nor by exper...
Although human immunodeficiency type 1 (HIV-1) infection induces strong antibody responses to the vi...
The generation of broadly neutralizing antibodies is a priority in the design of vaccines against HI...
<div><p>A comprehensive understanding of the regions on HIV-1 envelope trimers targeted by broadly n...
Human Immunodeficiency Virus (HIV-1) is an epidemic that affects over 34 million people worldwide. A...
The broadly neutralizing human monoclonal antibodies (MAbs) 2F5 and 4E10, both targeting the highly ...